Symbenda Post-Marketing Surveillance (PMS)

NCT02434484 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 84

Last updated 2021-01-26

No results posted yet for this study

Summary

This is a PMS of Symbenda Injection (bendamustine hydrochloride) in Korean Patients. The main objective is to obtain safety information related to Symbenda treatment from clinical practice.

Conditions

Sponsors & Collaborators

  • Eisai Korea Inc.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-04
Primary Completion
2020-03-20
Completion
2020-03-20

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02434484 on ClinicalTrials.gov